NOTE: This activity is available only as part of a paid subscription series; it is not available for purchase as a single, stand-alone activity.
The goal of this program is to improve the management of stage IIIA lung cancer, screening for lung cancer, and the management of lung cancer with specific mutations. After hearing and assimilating this program, the clinician will be better able to:
1. Differentiate between mediastinoscopy and endobronchial ultrasonography in invasive mediastinal staging for lung cancer.
2. Cite evidence from the CheckMate 816 trials regarding use of nivolumab in management of lung cancer.
3. Explain the effectiveness of low-dose computed tomography in screening for lung cancer.
4. List the US Preventive Services Task force updated eligibility criteria for screening for lung cancer.
5. Use osimertinib in management of EGFR-tyrosine kinase inhibitor-resistant tumors that harbor T790M mutation.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2022-08-29 05:00:00
- End Date: 2022-08-29 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all